Document is current
Any future updates will be listed below
-
Authors
Waks, Adrienne G
Keenan, Tanya E
Li, Tianyu
Tayob, Nabihah
Wulf, Gerburg M
Richardson, Edward T III
Attaya, Victoria
Anderson, Leilani
Mittendorf, Elizabeth A
Overmoyer, Beth
Winer, Eric P
Krop, Ian E
Agudo, Judith
Van Allen, Eliezer M https://orcid.org/0000-0002-0201-4444
Tolaney, Sara M https://orcid.org/0000-0002-5940-8671
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03032107 at ClinicalTrials.govnct04740918 at ClinicalTrials.govDocuments that mention this clinical trial
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
https://doi.org/10.1136/jitc-2022-005119
nct03199885 at ClinicalTrials.govDocuments that mention this clinical trial
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
https://doi.org/10.1136/jitc-2022-005119
nct03199885 at ClinicalTrials.govDocuments that mention this clinical trial
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
https://doi.org/10.1136/jitc-2022-005119
Documents that mention this clinical trial
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
https://doi.org/10.1136/jitc-2022-005119
-
Funding
Funding for this research was provided by:
Merck (N/A)
Rob and Karen Hale Distinguished Chair in Surgical Oncology (N/A)
- License Information
